Immunic (IMUX) Profit After Tax (2013 - 2026)

Immunic (IMUX) has 14 years of Profit After Tax data on file, last reported at -$32.6 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 27.93% year-over-year to -$32.6 million; the trailing twelve-month figure through Mar 2026 stood at -$105.8 million (down 9.81% YoY), and the FY2025 full-year result was -$98.7 million, up 1.77% from the prior year.
• Profit After Tax retreated to -$32.6 million in Q1 2026, from -$20.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$20.8 million in Q1 2022 to a low of -$56.5 million in Q4 2022.
• A 5-year average of -$26.2 million and a median of -$24.4 million in 2024 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax plunged 166.58% in 2022 and surged 61.8% in 2023, its largest moves.
• Tracing IMUX's Profit After Tax over 5 years: stood at -$56.5 million in 2022, then surged by 61.8% to -$21.6 million in 2023, then declined by 16.7% to -$25.2 million in 2024, then climbed by 17.14% to -$20.9 million in 2025, then tumbled by 56.21% to -$32.6 million in 2026.
• Business Quant data shows IMUX's Profit After Tax at -$32.6 million in Q1 2026, -$20.9 million in Q4 2025, and -$25.6 million in Q3 2025.